Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Nicolas Girard*, Jair Bar, Pilar Garrido, Marina C. Garassino, Fiona McDonald, Françoise Mornex, Andrea R. Filippi, Hans J.M. Smit, Solange Peters, John K. Field, Daniel C. Christoph, Anne Sibille, Rainer Fietkau, Vilde D. Haakensen, Christos Chouaid, Ben Markman, T. Jeroen N. Hiltermann, Alvaro Taus, William Sawyer, Allison AllenPratibha Chander, Muriel Licour, Benjamin Solomon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study'. Together they form a unique fingerprint.

Medicine & Life Sciences